JP2022537521A5 - - Google Patents

Info

Publication number
JP2022537521A5
JP2022537521A5 JP2021573829A JP2021573829A JP2022537521A5 JP 2022537521 A5 JP2022537521 A5 JP 2022537521A5 JP 2021573829 A JP2021573829 A JP 2021573829A JP 2021573829 A JP2021573829 A JP 2021573829A JP 2022537521 A5 JP2022537521 A5 JP 2022537521A5
Authority
JP
Japan
Prior art keywords
substituted
bispecific compound
pharmaceutically acceptable
compound according
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573829A
Other languages
English (en)
Japanese (ja)
Other versions
JP7626721B2 (ja
JP2022537521A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038130 external-priority patent/WO2020257278A2/en
Publication of JP2022537521A publication Critical patent/JP2022537521A/ja
Publication of JP2022537521A5 publication Critical patent/JP2022537521A5/ja
Application granted granted Critical
Publication of JP7626721B2 publication Critical patent/JP7626721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573829A 2019-06-18 2020-06-17 小分子標的ブロモ/アセチルタンパク質およびその使用 Active JP7626721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862879P 2019-06-18 2019-06-18
US62/862,879 2019-06-18
PCT/US2020/038130 WO2020257278A2 (en) 2019-06-18 2020-06-17 Small molecule target bromo/acetyl proteins and uses thereof

Publications (3)

Publication Number Publication Date
JP2022537521A JP2022537521A (ja) 2022-08-26
JP2022537521A5 true JP2022537521A5 (cg-RX-API-DMAC10.html) 2023-06-26
JP7626721B2 JP7626721B2 (ja) 2025-02-04

Family

ID=74037322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573829A Active JP7626721B2 (ja) 2019-06-18 2020-06-17 小分子標的ブロモ/アセチルタンパク質およびその使用

Country Status (7)

Country Link
US (1) US12496348B2 (cg-RX-API-DMAC10.html)
EP (1) EP3986470A4 (cg-RX-API-DMAC10.html)
JP (1) JP7626721B2 (cg-RX-API-DMAC10.html)
CN (1) CN114007652A (cg-RX-API-DMAC10.html)
AU (1) AU2020295399B2 (cg-RX-API-DMAC10.html)
CA (1) CA3143507A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020257278A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019371400B2 (en) * 2018-11-02 2024-10-17 Dana-Farber Cancer Institute, Inc. Acetylation writer inhibitor development and uses thereof
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
CN114989158A (zh) * 2021-03-02 2022-09-02 复旦大学 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用
WO2022257894A1 (zh) * 2021-06-07 2022-12-15 贝达药业股份有限公司 P300抑制剂及其在医药上的应用
CN118359600A (zh) * 2023-01-17 2024-07-19 中国科学院广州生物医药与健康研究院 一种芳基咪唑基异恶唑类化合物及其制备方法和应用
CN121005703A (zh) * 2024-05-24 2025-11-25 中国科学院广州生物医药与健康研究院 一种酰胺吲嗪类化合物及其制备方法和应用
CN119707936B (zh) * 2025-02-25 2025-07-25 中南大学 一种2,4-二取代-5-氟嘧啶衍生物的盐的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105979958A (zh) 2013-10-11 2016-09-28 基因泰克公司 Cbp/ep300布罗莫结构域抑制剂用于癌症免疫疗法的用途
CN107108512B (zh) 2014-10-10 2021-05-04 基因泰克公司 治疗性化合物及其用途
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197046A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4717317A3 (en) * 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
MX2020003190A (es) * 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
AU2019371400B2 (en) * 2018-11-02 2024-10-17 Dana-Farber Cancer Institute, Inc. Acetylation writer inhibitor development and uses thereof

Similar Documents

Publication Publication Date Title
IL278297B2 (en) Substituted heterocyclic inhibitors of ptpn11
JP2021511342A5 (cg-RX-API-DMAC10.html)
ES2750309T3 (es) Nuevos derivados de arilamida que tienen propiedades antiandrogénicas
JP2018502902A5 (cg-RX-API-DMAC10.html)
JP2009536620A5 (cg-RX-API-DMAC10.html)
JP2017528498A5 (cg-RX-API-DMAC10.html)
CA2448356A1 (en) N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
CN109843872A (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
JP2023538524A5 (cg-RX-API-DMAC10.html)
CN116113416A (zh) 四环类衍生物、其制备方法和其医药上的用途
JP2007505044A5 (cg-RX-API-DMAC10.html)
JP2023513793A5 (cg-RX-API-DMAC10.html)
EP0676201B1 (en) Use of a riminophenazine for treating MDR resistance
JP2015512430A (ja) 癌を治療するための官能性チエノ−インドール誘導体
JP2025041742A (ja) 薬学的組合せ
TW201641492A (zh) 經取代1,2,3-三唑、其用途、以及包含其之醫藥組成物
JPH01128962A (ja) 抗新生物剤としてのポリアミン誘導体類
JPWO2019031614A5 (cg-RX-API-DMAC10.html)
US20220194930A1 (en) Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same
JP2022502378A5 (cg-RX-API-DMAC10.html)
CA2504496A1 (en) N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
JP2005531563A5 (cg-RX-API-DMAC10.html)
RU2004111787A (ru) Ретиноидные агонисты (1), производные алкилмочевины
WO2015113521A1 (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
CA2485494A1 (en) Anti-tumour polycyclic carboxamides